EGFR and cancer: Conversely, cancer cells may suppress NK cell activation by reducing ULBP1 expression via the EGFR signaling pathway, thereby triggering immune escape.[353] Additionally, a novel peptide therapeutic agent, cSNX1.3 is designed to inhibit the reverse transport and nuclear localization of EGFR.